Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation.
Panag believes that pain relief should be safe, non-addictive and above all; effective.
Topical ß-caryophyllene 20% with 0.025% capsaicin
As co-founder and President of Panag Pharmaceuticals, Dr. Lynch is committed to leveraging her experience pain research and her clinical expertise to advance novel therapies for pain and inflammation.
As a co-founder and Chief Scientific Officer of Panag, Dr. Kelly brings extensive experience in drug development to lead the research and development of the pipeline products, with a particular emphasis on the ocular formulation.
Bill has over 20 years of experience in a wide variety of biotechnology fields, including vaccines, human genetics, drug development, manufacturing and extensive interactions with the pharmaceutical industry.
As a co-founder and Preclinical Director for Panag, Dr. Lehmann’s expertise in experimental and clinical intravital imaging and analysis of biomarkers of local and systemic inflammation is critical to the company’s evaluation of pre-clinical data from all product lines.
A co-founder in Panag, Dr. Hung brings not only depth of knowledge in clinical anesthesia and research, but also brings his product development and formulation optimization experience as co-inventor of AeroLEF®, a fentanyl product that is currently licensed to DELEX Therapeutics through YMBiosciences.
Topical A is the only topical pain relief cream specifically formulated to leverage the endocannabinoid system (ECS), which is the body’s built-in pain and inflammation defense system. Over the last decade, Panag scientists and medical doctors have been researching ways to exploit the ECS in order to find new ways to treat pain and inflammation.
Learn more about the endocannabinoid system and how it helps fight pain and inflammation